Overview

Stem Cell Transplantation for Patients With Multiple Myeloma

Status:
Active, not recruiting
Trial end date:
2022-09-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether regulatory T-cell reduction is possible and safe in myeloma subjects undergoing autologous stem cell transplantation (ASCT).
Phase:
Phase 1
Details
Lead Sponsor:
University of Chicago
Treatments:
Basiliximab
JM 3100
Melphalan
Plerixafor